Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Adjuvant Pazopanib for Renal Cell Carcinoma
NCT02307474Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pazopanib in clear cell renal cell carcinoma (ccRCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Incidence of grade 3 and above NCI CTCAE v4.0 toxicity. Planned start Sep 2015; status: withdrawn.
02
Drugs
pazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02307474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307474.